Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018.

Authors

Kazuto Nakamura

Department of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan

Kazuto Nakamura , Akira Yabuno , Toyomi Satoh , Hiroyuki Fujiwara , Akira Kurosaki , Soichi Yamashita , Toshihiro Misumi , Shin-ei Noda , Kosei Hasegawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

First Author: Igor Tsaur

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

First Author: Julie R. Brahmer

insert_chart_outlined

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

bookmark_border

Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.

First Author: Sant P. Chawla

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.

First Author: Manish A. Shah